Introduction

The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.

Scope

• An overview of the current Hepatitis C market and its key players
• In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
• Epidemiological dynamics of Hepatitis C in the six major markets are discussed along with unmet needs
• 10 year sales forecasts for marketed and six pipeline drugs

Highlights

Given its large patient potential and significant unmet needs, the Hepatitis C market has attracted considerable interest from companies with a strong presence in infectious diseases. The HCV pipeline is therefore very active and consists of drugs with various mechanisms of action.

Several strategies are being explored in clinical trials, including add-on therapy to the current standard of care, interferon replacement and ribavirin replacement. Of these Datamonitor believes that add-on therapy will be the most successful in the medium term.

The two most advanced pipeline candidates are Schering Plough's boceprevir and Vertex's telaprevir. Both drugs have demonstrated comparable efficacy benefits when combined with current standard of care. Datamonitor expects telaprevir to gain higher market share due to its ability to cut short the overall duration of therapy in genotype 1 patients.

Reasons to Purchase

• Understand current and future Hepatitis C market dynamics
• Gain insight into the unmet needs of HCV patients and the extent to which pipeline drugs are addressing these issues
• Evaluate the Hepatitis C market forecast for existing and key pipeline drugs to 2018

View Table Of Contents >